ArticleMetabolic brain disease2025
Brain morphological changes in type 2 diabetes patients with painful peripheral neuropathy.
Article in Metabolic brain disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Pain Modulation and Central Sensitization in Painful Diabetic Peripheral Neuropathy: Updated Narrative Review and Future Directions.Journal of diabetes · 2026Review
- The role of brain mechanisms in diabetic peripheral neuropathy: recent advances and comprehensive analysis.Frontiers in cellular neuroscience · 2025Review
- The intrinsic reason why complementary tests (clinical neurophysiology, neuroimaging, skin biopsy) cannot establish the diagnosis of neuropathic pain.Frontiers in pain research (Lausanne, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We investigates changes in brain volume and cortical thickness in patients with type 2 diabetes mellitus (T2DM) and peripheral neuropathy (DPN), particularly those with neuropathic pain. 105 participants were divided into three groups: T2DM (n = 26), T2DM with DPN (n = 42), and healthy controls (HCs, n = 37). The DPN group was further divided into painless (n = 22) and painful (n = 20) subgroups. Participants underwent clinical neuropsychological testing, electromyography, and brain MRI scans. Voxel-based morphometry was used to analyze gray matter volume (GMV) and cortical thickness. Associations between morphological changes and clinical/neuropsychological indicators were assessed. Average cortical thickness of the three patient subgroups was significantly reduced compared to the HCs. GMV loss in the DPN_ pain group was confined to the cerebellum, right putamen/pallidum, and caudate, while GMV increased in the brainstem. Multiple regression analysis showed correlations between brain regions and factors such as cholesterol levels, neuropathic pain severity, and nerve amplitudes (P < 0.001). The volume of right lateral geniculate nucleus volume was linked to the DN4 score (r = 0.593, P = 0.015) and onset age (r = -0.541, P = 0.031). Specific brain regions and the cortices are more vulnerable to the effects of neuropathic pain and peripheral nerve damage.
Indexed as
Identifiers
40448742What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.